Table 2.
Meta-analyses on PET/CT with PSMA-targeted agents in prostate cancer.
| Authors | Year | Articles | Patients | Topic | Pooled Sensitivity | Pooled Specificity | Pooled LR+ | Pooled LR− | Pooled DOR | Pooled DR |
|---|---|---|---|---|---|---|---|---|---|---|
| Tan et al. [32] | 2020 | 38 | 3217 | Restaging | NA | NA | NA | NA | NA | NA (*) |
| Kimura et al. [21] | 2020 | 9 | NA | Restaging | 0.84 | 0.97 | 30.3 | 0.16 | 189 | NA |
| Wu et al. [23] | 2020 | 13 | 1597 | Staging | 0.65 | 0.94 | 10.6 | 0.37 | 29 | NA |
| Perera et al. [24] | 2020 | 37 | 4790 | Staging/restaging | 0.77 | 0.97 | NA | NA | NA | NA |
| Tan et al. [31] | 2019 | 43 | 5113 | Restaging | NA | NA | NA | NA | NA | 0.70 |
| Treglia et al. [3] | 2019 | 5 | 257 | Restaging | NA | NA | NA | NA | NA | 0.78 |
| Zhou et al. [4] | 2019 | 6 | NA | Detection of bone metastases | 0.97 | 1.00 | NA | NA | NA | NA |
| Treglia et al. [22] | 2019 | 6 | 645 | Restaging | NA | NA | NA | NA | NA | 0.81 |
| Lin et al. [6] | 2019 | 13 | 652 | Staging/restaging | 0.92 | 0.94 | 7.91 | 0.14 | 79.04 | NA |
| Pereira Mestre et al. [25] | 2019 | 8 | NA | Restaging | NA | NA | NA | NA | NA | 0.72 |
| Hope et al. [26] | 2019 | 29 | NA | Staging/restaging | 0.74/0.99 | 0.96/0.76 | NA | NA | NA | NA |
| Kim et al. [27] | 2019 | 6 | 298 | Staging | 0.71 | 0.95 | 15.6 | 0.30 | 51 | NA |
| Han et al. [28] | 2018 | 15 | 1163 | Impact on management | NA | NA | NA | NA | NA | NA |
| Von Eyben et al. [29] | 2018 | 15 | 1256 | Staging/restaging | 0.61–0.7/0.87–0.93 | 0.84–0.97/0.93–1 | NA | NA | NA | 0.74/0.81 |
| Perera et al. [30] | 2016 | 16 | 1309 | Staging/restaging | 0.86 | 0.86 | NA | NA | NA | 0.40/0.76 |
Legend: NA = not available; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; DR = detection rate; (*) = only available for PSA < 2 ng/mL.